Novo Nordisk ADR (NYSE: NVO)’s stock price has gone rise by 0.08 in comparison to its previous close of 62.55, however, the company has experienced a -9.85% decrease in its stock price over the last five trading days. reuters.com reported 2025-04-07 that Novo Nordisk, the producer of Ozempic and other medications, announced on Monday a 6.4 billion reais ($1.09 billion) investment in Brazil to boost production.
Is It Worth Investing in Novo Nordisk ADR (NYSE: NVO) Right Now?
The price-to-earnings ratio for Novo Nordisk ADR (NYSE: NVO) is 19.07x, which is above its average ratio. Moreover, the 36-month beta value for NVO is 0.68. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 1 as “sell.”
The public float for NVO is 3.36B and currently, short sellers hold a 0.38% of that float. On April 07, 2025, NVO’s average trading volume was 8.56M shares.
NVO’s Market Performance
NVO stock saw a decrease of -9.85% in the past week, with a monthly decline of -28.19% and a quarterly a decrease of -28.58%. The volatility ratio for the week is 3.39%, and the volatility levels for the last 30 days are 2.56% for Novo Nordisk ADR (NVO). The simple moving average for the last 20 days is -14.23% for NVO’s stock, with a simple moving average of -42.42% for the last 200 days.
NVO Trading at -22.28% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.75% of loss for the given period.
Volatility was left at 2.56%, however, over the last 30 days, the volatility rate increased by 3.39%, as shares sank -19.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.42% lower at present.
During the last 5 trading sessions, NVO fell by -8.05%, which changed the moving average for the period of 200-days by -54.65% in comparison to the 20-day moving average, which settled at $73.05. In addition, Novo Nordisk ADR saw -27.23% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.44 for the present operating margin
- 0.85 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.35. The total capital return value is set at 0.52. Equity return is now at value 82.03, with 26.33 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at 1.18. The debt to equity ratio resting at 0.72. The interest coverage ratio of the stock is 28.85.
Currently, EBITDA for the company is 137.38 billion with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 7.17. The receivables turnover for the company is 3.32for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To wrap up, the performance of Novo Nordisk ADR (NVO) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
